Bank of Montreal’s Rigel Pharmaceuticals RIGL Stock Holding History

Bank of Montreal’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-50	Closed	-$1K	–	4979
2019 Q3	$1K	Buy	+50	New	+$1.03K	﹤0.01%	4682

Other funds holding RIGL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of Montreal's RIGL Position: Q1 2026 in Review

Bank of Montreal sold out of Rigel Pharmaceuticals (RIGL) in Q1 2026, closing a stake of 4,858 shares — an estimated $208K sold.

Bank of Montreal first reported a position in RIGL in Q3 2013 and held it in 28 quarters. The position peaked at $1.51M in Q2 2021. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.

Bank of Montreal reported no remaining Rigel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Bank of Montreal sold 4,858 Rigel Pharmaceuticals shares in Q1 2026, an estimated $208K.
Bank of Montreal first reported a position in Rigel Pharmaceuticals in Q3 2013 and held it in 28 quarters.
Bank of Montreal's Rigel Pharmaceuticals position peaked at $1.51M in Q2 2021.
159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.

Based on Bank of Montreal's 13F filing for Q1 2026, filed 13 May 2026.